In The News

Health Care Partner Addresses FDA Bid to Lower Drug Prices in The Washington Post

Practices: Health Care, Life Sciences, FDA Regulatory

Capital Insights.

Health care partner Tom Bulleit (Washington, D.C.) addressed the U.S. Food & Drug Administration’s bid to lower drug prices in a July 18 article published in The Washington Post that was reprinted in The San Francisco Chronicle and Connecticut Post.

Mr. Bulleit expressed skepticism that policy actions suggested so far by FDA, which has no official role in how drug prices are set, would result in significant decreases in list prices for prescription drugs, or the out-of-pocket costs of any substantial number of health care consumers.

Cookie Settings